Trial · NCT02606539
Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms
NCT02606539, Phase 2, Phase 3, Unknown, Maher elesawi kamel elesawi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms. Trials, record NCT02606539. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02606539
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms
- NCT number
- NCT02606539
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Maher elesawi kamel elesawi
- Conditions
- Gestational Trophoblastic Neoplasms
- Interventions
- Total abdominal hysterectomy and methotrexate, Methotrexate plus folinic acid alone
- First posted
- 2015-11-17
- Last updated
- 2017-03-22
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | number of primary chemotherapy courses till B-hCG reach less than 5 MU/ML | 1-6 months | |
| Secondary | quality of life( questionairre) | 1-6 months | pain scale from zero to 11, return to ordinary activities |
| Secondary | complications from management | 1-6 months | renal, hepatic impairments, anemia, |
| Secondary | time interval for B-hCG reach less than 5 MU/ML | 1-6 months | the time taken for B-hCG to reach below 5 MU/ML |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02606539
GET https://conductscience.org/api/trials/v1/NCT02606539/registered